TrialJournal of neuro-oncology2017

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.

Mark R Gilbert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.